|
|
|
| Effects of Metformin Combined with Pioglitazone on Body Fat Composition, α and β Cell Function in Patients with Schizophrenia and Type 2 Diabetes Mellitus |
| YANG Jun-lan, XIONG Rui-cai |
| Department of medicine, Pengzhou Fourth People's Hospital, Peng Zhou, Sichuan 611933 China |
|
|
|
|
Abstract 【Objective】To analyze the effect of early hypoglycemic agents (metformin and pioglitazone) on the changes in body fat composition, α and β cell function in patients with schizophrenia (SP) and type 2 diabetes mellitus (T2DM).【Methods】A total of 180 patients with SP and T2DM treated in our hospital from January 2015 to June 2016 were selected in the study. Patients were divided into the control group and the observation group by random number table method, with 90 cases in each group. Both groups were given routine basic treatment. The control group was treated with metformin while the observation group was treated with metformin and pioglitazone. Changes in glucose metabolism, body fat composition, α and β cell function before and after treatment were determined and the therapeutic effects were compared between the two groups. The incidence of adverse reactions was statistically analyzed.【Results】After treatment, the fasting blood glucose (FPG), postprandial 2h blood glucose (2hPG) and glycosylated hemoglobin (HbA1c) in the two groups were decreased (P<0.05), but the decrease of 2hPG was more obvious in the observation group than in the control group (P<0.05). After the treatment, the insulin resistance index (HOMA-IR) was decreased and insulin secretion index HOMA-β was increased in both groups (P<0.05). HOMA-β was higher in the observation group than the control group, while HOMA-IR and glucagon levels were lower in the observation group than the control group (P<0.05). After treatment, the total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) were decreased, while triglyceride (TG) and high-density lipoprotein (HDL-C) were increased (P<0.05). The levels of TC and LDL-C in observation group after treatment were lower than those in the control group (P<0.05). After treatment, the body weight and body fat percentage (BF) in the observation group were lower than those in the control group (P<0.05), and there was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).【Conclusion】The body fat percentage is high, function of islet α and β cells is decreased in patients with SP and T2DM. The early treatment with metformin and pioglitazone can improve the body fat composition and optimize the function of islet α and β cells.
|
|
Received: 25 April 2017
|
|
|
|
|
|
[1]陈彬,张星光,程千鹏,等.艾塞那肽联合二甲双胍对初诊成人2型糖尿病患者血糖控制效果观察[J].解放军医药杂志,2016,28(5):66-69.
[2]敖磊,何长江,郭娟,等.糖尿病对精神分裂症患者认知功能的影响[J].昆明医科大学学报,2014,35(9):109-112.
[3]许勤伟,刘向来.并发糖尿病的精神分裂症患者门诊急诊临床特征分析[J].中国医药导报,2013,10(13):31-32,35.
[4]陈俊雄,吴树跃,彭红梅,等.合并糖尿病对老年精神分裂症患者临床和认知功能的影响[J].河北医学,2012,18(8):1048-1051.
[5]中华医学会精神科分会.CCMD-3中国精神障碍分类与诊断标准[M].山东:山东科学技术出版社,2001:174-176.
[6]蒋国彦.糖尿病:世界卫生组织糖尿病专家委员会第2次报告[M].北京:人民卫生出版社,1982:16-17.
[7]许又新.对《精神分裂症防治指南》的意见[J].中国心理卫生杂志,2011,25(1):26-27.
[8]梁怡,重远.利拉鲁肽对超重或肥胖的2型糖尿病的疗效分析[J].湖南师范大学学报(医学版),2016,13(2):75-77.
[9]范毅敏,杨程青,胡国芹,等.精神分裂症与糖尿病共病流行病学、临床特征及发病机制新进展[J].中华临床医师杂志(电子版),2014,8(15):2857-2860.
[10]严婷,杨锐,余丹峰,等.吡格列酮二甲双胍片或二甲双胍治疗对2型糖尿病患者的多种脂肪细胞因子的影响[J].中华内分泌代谢杂志,2013,29(6):509-511.
[11]杜守作.吡格列酮结合二甲双胍治疗2型糖尿病的临床疗效[J].医学临床研究,2011,28(10):1941-1943.
[12]吕飞娟,杨燕玲,杜娟,等.吡格列酮对2型糖尿病患者血糖、血脂、C反应蛋白的影响[J].医学临床研究,2011,28(11):2181-2183.
[13]李艳玲,张星光,陈彬,等.维格列汀对新诊断2型糖尿病的疗效及对血糖波动的影响研究[J].中国全科医学,2014,17(28):3350-3352,3355. |
| [1] |
. [J]. JOURNAL OF CLINICAL RESEARCH, 2017, 34(9): 1773-1775. |
|
|
|
|
2017, Vol. 34 
